Phase II study of carbetimer in non-small cell lung cancer.
Keaton
M
M
Brooke Army Medical Center, Fort Sam Houston, TX.
Brown
T
T
Craig
J
J
Fries
G
G
Harmon
G
G
Zaloznik
A
A
Orczyk
G
G
Von Hoff
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011108:Polymers / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011108:Polymers; C022084:carboxyimamidate